Vision loss after chemotherapy: an irinotecan-induced retinopathy

•Irinotecan is a topoisomerase-I inhibitor widely used for gastrointestinal tumours.•Vision loss has never been reported after irinotecan infusion.•Irinotecan-induced retinopathy has never been reported so far.•This toxicity is characterised by a diffuse loss of photoreceptors' outer segments.•...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2019-05, Vol.112, p.80-82
Main Authors: Boilève, Alice, Jozwiak, Mathieu, Malka, David, Boige, Valérie, Le Roy, Florence, Paques, Michel, Ducreux, Michel
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy
Colonic Neoplasms - drug therapy
Female
Humans
Irinotecan
Irinotecan - adverse effects
Irinotecan - therapeutic use
Middle Aged
Photoreceptors
Retinal Diseases - chemically induced
Retinopathy
Toxicity
Vision Disorders - chemically induced
Vision loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Irinotecan is a topoisomerase-I inhibitor widely used for gastrointestinal tumours.•Vision loss has never been reported after irinotecan infusion.•Irinotecan-induced retinopathy has never been reported so far.•This toxicity is characterised by a diffuse loss of photoreceptors' outer segments.•Further studies are required to better characterise irinotecan-induced retinopathy.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2019.02.015